| Measure Title: |
RELATING TO ACCESS TO TREATMENT FOR TERMINALLY ILL PATIENTS.
|
| Report Title: |
Right-to-Try Act; Terminally Ill Patients; Investigational Drugs; Biological Products
|
| Description: |
Beginning on January 1, 2024, permits manufacturers of investigational drugs or biological products to make these drugs and products available to terminally ill patients under certain conditions.
|
| Companion: |
SB857
|
| Package: |
None
|
| Current Referral: |
HLT, CPC, FIN
|
| Introducer(s): |
BELATTI, AMATO, GANADEN, GATES, HUSSEY-BURDICK, LAMOSAO, MARTEN, MATAYOSHI, MIZUNO, NAKASHIMA, NISHIMOTO, PERRUSO, TAKENOUCHI, TARNAS, TODD, Poepoe
|
| Act: |
|
| Sort by Date | | Status Text |
| 1/30/2023 | H | Referred to HLT, CPC, FIN, referral sheet 3 |
| 1/25/2023 | H | Introduced and Pass First Reading. |
| 1/23/2023 | H | Pending introduction. |
S = Senate |
H = House |
D = Data Systems |
$ = Appropriation measure |
ConAm = Constitutional Amendment
Some of the above items require Adobe Acrobat Reader. Please visit
Adobe's download page
for detailed instructions.
HB966